Pass medicine Flashcards
Secondary hypothyroidism is caused by pituitary failure and needs imaging
- C-peptide levels and diabetes-specific autoantibodies are useful to distinguish between type 1 and type 2 diabetes
- C-peptide levels are typically low in patients with T1DM
The PTH level in primary hyperparathyroidism may be normal
Causes of raised prolactin - the p’s
pregnancy
prolactinoma
physiological
polycystic ovarian syndrome
primary hypothyroidism
phenothiazines, metoclopramide, domperidone
Pioglitazone - increases the risk of bladder cancer
Sick euthyroid syndrome = low T3/T4 and normal TSH with acute illness
Metabolic ketoacidosis with normal or low glucose: think alcohol
Sulfonylureas - bind to an ATP-dependent K+(KATP) channel on the cell membrane of pancreatic beta cells
Indications for starting - Levothyroxine 25mg
- patients with cardiac disease,
- severe hypothyroidism
- patients over 50 years
the initial starting dose should be 25mcg od with dose slowly titrated
Other patients should be started on a dose of 50-100mcg od
Initiating thyroxine therapy
- following a change in thyroxine dose thyroid function tests should be checked after 8-12 weeks
- the therapeutic goal is ‘normalisation’ of the thyroid stimulating hormone (TSH) level.
- As the majority of unaffected people have a TSH value 0.5-2.5 mU/l it is now thought preferable to aim for a TSH in this range
Thyroxine in pregnancy
women with established hypothyroidism who become pregnant should have their dose increased ‘by at least 25-50 micrograms levothyroxine’* due to the increased demands of pregnancy.
Side-effects of thyroxine therapy
hyperthyroidism: due to over treatment
reduced bone mineral density
worsening of angina
atrial fibrillation
Thyroxine - interactions
iron, calcium carbonate
absorption of levothyroxine reduced, give at least 4 hours apart
Thyroxine - over replacement
- recent TFTs show a suppressed TSH indicating over replacement. Even though she is asymptomatic the dose should be decreased to reduce the risk of osteoporosis and atrial fibrillation. The BNF recommends adjusting the dose by 25mcg in this age group.